Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Dr. Reddy's Laboratories Limited, India Clear all

Conditions: Psoriasis
Interventions: PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 74
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 54 more

Conditions: Healthy
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Broadway, Florida

Conditions: Healthy
Interventions: Zonisamide, Zonegran; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Acne Vulgaris
Interventions: Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 9 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Persistent or Recurrent Cutaneous T-Cell Lymphoma
Interventions: E7777 9 mcg/kg; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 12 more

Conditions: Fasting
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Follicular Lymphoma
Interventions: DRL_RI (Proposed rituximab biosimilar), MabThera®; Biological · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Whittier, California • Bethesda, Maryland • Knoxville, Tennessee + 1 more

Conditions: Surgical Site Infection
Interventions: DFA-02, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Florence, Alabama • Tampa, Florida • Columbus, Ohio + 2 more

Conditions: Acne Vulgaris
Interventions: DFD-03, Placebo Comparator; Drug · Other
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 9 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Pediculosis
Interventions: Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Head Lice Infestation
Interventions: Abametapir Lotion 0.74% w/w, Vehicle Lotion; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 6 Months and older
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 7
States / cities: Dinuba, California • Los Angeles, California • West Palm Beach, Florida + 4 more

Conditions: Healthy
Interventions: Finasteride; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Migraine With Aura, Migraine Without Aura, Allodynia
Interventions: DFN-15, Placebo; Drug · Other
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 64 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: West Hartford, Connecticut

Conditions: Healthy
Interventions: Zonisamide, Zonegran; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Surgical Site Infections
Interventions: DFA-02 Antibiotic Gel, DFA-02 Placebo Gel; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 31
States / cities: Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 28 more

Conditions: Pediculosis
Interventions: Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44 Gel 0.74% w/w, Group C - Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 2 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Dinuba, California • Los Angeles, California

Conditions: Rosacea
Interventions: Minocycline hydrochloride capsules, Placebo; Drug · Other
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Las Cruces, New Mexico • El Paso, Texas

Conditions: Acute Migraine
Interventions: DFN-02; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Phoenix, Arizona • Long Beach, California • Redding, California + 21 more

Conditions: Healthy
Interventions: Isotretinoin; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Quadrangle Drive, Chapel Hill,, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®; Biological
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Phoenix, Arizona • Palmdale, California • Upland, California + 18 more

Conditions: Healthy
Interventions: Lamotrigine, Lamictal®; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 20 Years to 44 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Quadrangle Drive, North Carolina

Conditions: Healthy
Interventions: Desloratadine; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Broadway, Florida

Conditions: Rheumatoid Arthritis
Interventions: Test Product, Reference product, Reference Medicinal Product; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Conditions: Chronic Idiopathic Constipation
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 93
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 71 more

Search by objective public record fields.

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma

Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

DFA-02 in Patients Undergoing Colorectal Surgery

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions

Can DFN-15 Terminate Migraine With Allodynia?

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery

An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

DFN-02 Open Label Safety Study in Patients With Acute Migraine

Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition

Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by the Subcutaneous Route

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation